Troponin measurements in ischemic heart disease: More than just a black and white pictureANTMAN, Elliott M.Journal of the American College of Cardiology. 2001, Vol 38, Num 4, pp 987-990, issn 0735-1097Article

The search for replacements for unfractionated heparinANTMAN, Elliott M.Circulation (New York, N.Y.). 2001, Vol 103, Num 18, pp 2310-2314, issn 0009-7322Article

Evidence and EducationANTMAN, Elliott M.Circulation (New York, N.Y.). 2011, Vol 123, Num 6, pp 681-685, issn 0009-7322, 5 p.Article

Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: Appropriate interpretation of the guidelinesANTMAN, Elliott M.The American heart journal. 2003, Vol 146, Num 4, pp S18-S22, issn 0002-8703, SUPConference Paper

Time Is Muscle : Translation Into PracticeANTMAN, Elliott M.Journal of the American College of Cardiology. 2008, Vol 52, Num 15, pp 1216-1221, issn 0735-1097, 6 p.Article

Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromesCOHEN, Marc; ANTMAN, Elliott M.Pharmacotherapy. 2002, Vol 22, Num 4, pp 542-550, issn 0277-0008Article

PrasugrelWIVIOTT, Stephen D; ANTMAN, Elliott M; BRAUNWALD, Eugene et al.Circulation (New York, N.Y.). 2010, Vol 122, Num 4, pp 394-403, issn 0009-7322, 10 p.Article

Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?ANTMAN, Elliott M; FERGUSON, James J.Circulation (New York, N.Y.). 2003, Vol 108, Num 21, pp 2604-2607, issn 0009-7322, 4 p.Article

Clopidogrel resistance: A new chapter in a fast-moving storyWIVIOTT, Stephen D; ANTMAN, Elliott M.Circulation (New York, N.Y.). 2004, Vol 109, Num 25, pp 3064-3067, issn 0009-7322, 4 p.Article

Bolus fibrinolytic therapy in acute myocardial infarctionLLEVADOT, Joan; GIUGLIANO, Robert P; ANTMAN, Elliott M et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 4, pp 442-449, issn 0098-7484Article

Low-molecular-weight heparins in the treatment of acute coronary syndromesTURPIE, Alexander G. G; ANTMAN, Elliott M.Archives of internal medicine (1960). 2001, Vol 161, Num 12, pp 1484-1489, issn 0003-9926Article

Cyclooxygenase inhibition and cardiovascular riskANTMAN, Elliott M; DEMETS, David; LOSCALZO, Joseph et al.Circulation (New York, N.Y.). 2005, Vol 112, Num 5, pp 759-770, issn 0009-7322, 12 p.Article

2007 Focused Update to the ACC/AHA Guidelines for the Management of Patients With ST-Segment Elevation Myocardial Infarction : Implications for Emergency Department PracticePOLLACK, Charles V; ANTMAN, Elliott M; HOLLANDER, Judd E et al.Annals of emergency medicine. 2008, Vol 52, Num 4, pp 344-355, issn 0196-0644, 12 p.Article

Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary interventionWONG, Graham C; GIUGLIANO, Robert P; ANTMAN, Elliott M et al.JAMA, the journal of the American Medical Association. 2003, Vol 289, Num 3, pp 331-342, issn 0098-7484, 12 p.Article

Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromesCOHEN, Marc; ANTMAN, Elliott M; MURPHY, Sabina A et al.The American heart journal. 2002, Vol 143, Num 1, pp 63-69, issn 0002-8703Article

Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: Does the choice of fibrinolytic agent impact on the importance of time-to-treatment?NALLAMOTHU, Brahmajee K; ANTMAN, Elliott M; BATES, Eric R et al.The American journal of cardiology. 2004, Vol 94, Num 6, pp 772-774, issn 0002-9149, 3 p.Article

The re-emergence of anticoagulation in coronary diseaseANTMAN, Elliott M.European heart journal supplements. 2004, Vol 6, Num B, pp B2-B8, issn 1520-765XArticle

Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trialANTMAN, Elliott M; MCCABE, Carolyn H; BRAUNWALD, Eugene et al.The American heart journal. 2002, Vol 143, Num 2, pp 229-234, issn 0002-8703Article

Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Every minute of delay countsDE LUCA, Giuseppe; SURYAPRANATA, Harry; OTTERVANGER, Jan Paul et al.Circulation (New York, N.Y.). 2004, Vol 109, Num 10, pp 1223-1225, issn 0009-7322, 3 p.Article

Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary interventionFOX, Keith A. A; ANTMAN, Elliott M; COHEN, Marc et al.The American journal of cardiology. 2002, Vol 90, Num 5, pp 477-482, issn 0002-9149Article

New heparin dosing recommendations for patients with acute coronary syndromesMENON, Venu; BERKOWITZ, Scott D; ANTMAN, Elliott M et al.The American journal of medicine. 2001, Vol 110, Num 8, pp 641-650, issn 0002-9343Article

Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare BeneficiariesCHOUDHRY, Niteesh K; PATRICK, Amanda R; ANTMAN, Elliott M et al.Circulation (New York, N.Y.). 2008, Vol 117, Num 10, pp 1261-1268, issn 0009-7322, 8 p.Article

The Thrombolysis In Myocardial Infarction risk score in unstable angina/ non-st-segment elevation Myocardial InfarctionSABATINE, Marc S; ANTMAN, Elliott M.Journal of the American College of Cardiology. 2003, Vol 41, Num 4, pp 89-95, issn 0735-1097, 7 p., SUPSArticle

Development of systems of care for ST-elevation myocardial infarction patients : Executive summaryJACOBS, Alice K; ANTMAN, Elliott M; FAXON, David P et al.Circulation (New York, N.Y.). 2007, Vol 116, Num 2, pp 217-230, issn 0009-7322, 14 p.Article

Diabetes and mortality following acute coronary syndromesDONAHOE, Sean M; STEWART, Garrick C; MCCABE, Carolyn H et al.JAMA, the journal of the American Medical Association. 2007, Vol 298, Num 7, pp 765-775, issn 0098-7484, 11 p.Article